Low treatmentadherence
Poor adherence to treatments has been associated with an increase number of patients with multi-chronic diseases. These parallels have contributed to compromised patient outcomes and an increase in healthcare costs. Improving treatment adherence is becoming a key priority for healthcare actors to balance the cost of our healthcare systems.
Global economic pressure on pharma sector
Pharma companies have to cope with governments pressure to contain healthcare expenditure. In Europe, growth rates are declining and valued at 1-4% over the next 5 years in comparison to previous years which was 5%. In this context, efficiency, profitability, and innovative approaches are necessary to safeguard sustainable growth in the industry.
Generic drugscompetition
90% of the current Top 20 world drugs will compete against a generic or biosimilar drug by 2023. The loss of revenues is estimated at nearly $120 billion in developed country markets (2019-2023). Shortening the period of active promotion of Rx products requires offensive and efficient commercial strategies.
Beyond the pillapproach
Governments, patients and HCP’s all expect pharma companies to bring added value support for health products, which implies offering a full range of services throughout the product life cycle. Added value services such as Patients Support Programs are the new excepted model: scientific projects with MSLs, web conferences with KOLs, mobile apps for healthcare practitioners and patients, drug delivery, patient support programs etc.
Low treatment adherence
Poor adherence to treatments has been associated with an increase number of patients with multi-chronic diseases. These parallels have contributed to compromised patient outcomes and an increase in healthcare costs. Improving treatment adherence is becoming a key priority for healthcare actors to balance the cost of our healthcare systems.
Global economic pressureon pharma sector
Pharma companies have to cope with governments pressure to contain healthcare expenditure. In Europe, growth rates are declining and valued at 1-4% over the next 5 years in comparison to previous years which was 5%. In this context, efficiency, profitability, and innovative approaches are necessary to safeguard sustainable growth in the industry.
Generic drugs competition
90% of the current Top 20 world drugs will compete against a generic or biosimilar drug by 2023. The loss of revenues is estimated at nearly $120 billion in developed country markets (2019-2023). Shortening the period of active promotion of Rx products requires offensive and efficient commercial strategies.
Beyond the pill approach
Governments, patients and HCP’s all expect pharma companies to bring added value support for health products, which implies offering a full range of services throughout the product life cycle. Added value services such as Patients Support Programs are the new excepted model: scientific projects with MSLs, web conferences with KOLs, mobile apps for healthcare practitioners and patients, drug delivery, patient support programs etc.
Why we are the perfect match
Our Efficiency
Relying on Consultants, Pharmacists & Doctors, Nurses & Certified Medical Reps, we have a long-standing experience in supporting our customers in their evolving markets.
Our Quality
More than 100 pharma companies, hospitals, insurance companies trust our ability to help them to face their new challenges: increasing the digital share in promotion, facing competition from generic players and developing innovative services.
Our Innovation
Innovation is part of our DNA. Pioneer in direct sales, hybrid promotion and patients support programs, we aim at designing new healthcare models. Our track-record for innovation is enhanced with 20 years of valuable behavioural data collected from French pharmicists and doctors. This has enabled us to create fully customizable proprietary tools and a hybrid approach for their preferences.
Client stories
Client stories
Latest news about Healthcare
